Global Automation in Biopharmaceutical Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
The global biopharmaceutical industry is the most rapidly growing industry in the science and technology sector owing to increasing R&D investments in biopharmaceutical drug development facilities. The global automation market in biopharmaceutical industry includes deployment of automation in biopharmaceutical academic research centers, manufacturing and research companies, clinical labs, and government approved labs.
One trend in the market is continuous manufacturing. Advantages of continuous operations are well-recognized in various industries. It completes the process in a shorter time as it omits the hold steps, reduces shut down time, and reduces the labor requirement. Over the decades, upstream processing utilized this technology.”
According to the report, one driver in the market is use of automation in data acquisition. Traditionally, research labs collect data manually and store it in spreadsheets. This method is not only time-consuming but also affects operational efficiency and is prone to errors. It also restricts monitoring of data in real time. The biopharmaceutical industry is working on data collection and adding the information from spreadsheets to a database. Database collection of upstream and downstream processes is being utilized to create a library that increases operational efficiency and process optimization.
Further, the report states that one challenge in the market is high R&D cost. The biopharmaceutical industry is a rapidly growing industry in pharmaceuticals. Complex drugs are manufactured with the help of 3-D modeling and are produced with high efficacy and precision. These drugs can provide medication to medical issues that were once incurable. Currently, the biopharmaceutical industry is looking to yield new products to address diseases such as cancer, Alzheimer's disease, and hepatitis C. Innovations in the biopharmaceutical industry are highly expensive. The average cost associated with a new drug is around $2 billion, including the cost of unsuccessful drug approvals, out of which almost $400 million is the cost included in pre-clinical and clinical testing.

The global Automation in Biopharmaceutical market is valued at 1040 million US$ in 2018 is expected to reach 1590 million US$ by the end of 2025, growing at a CAGR of 6.2% during 2019-2025.
This report focuses on Automation in Biopharmaceutical volume and value at global level, regional level and company level. From a global perspective, this report represents overall Automation in Biopharmaceutical market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Danaher
    GE
    PerkinElmer
    Tecan Trading
    Thermo Fisher Scientific
    Bruker
    Peak Analysis & Automation
    Waters
    Capsugel
    RheoSense
    Eirechrom
    BioProcess International
    Novasep

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Clinical stage automation
    Drug discovery stage automation

Segment by Application
    Research and Development
    Clinical